Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy

Hait, 2005, Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it, Semin Oncol, 32, S16, 10.1053/j.seminoncol.2005.09.011 Perez-Tomas, 2006, Multidrug resistance: retrospect and prospects in anti-cancer drug treatment, Curr Med Chem, 13, 1859, 10.2174/092986706777585077 Gonzalez-Angulo, 2007, Overview of resistance to systemic therapy in patients with breast cancer, Adv Exp Med Biol, 608, 1, 10.1007/978-0-387-74039-3_1 Wilson, 2009, Anti-apoptotic mechanisms of drug resistance in cancer, Curr Cancer Drug Targets, 9, 307, 10.2174/156800909788166547 Szakacs, 2006, Targeting multidrug resistance in cancer, Nat Rev Drug Discov, 5, 219, 10.1038/nrd1984 Liu, 2001, Ceramide glycosylation potentiates cellular multidrug resistance, FASEB J, 15, 719, 10.1096/fj.00-0223com Wu, 2008, Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies, Curr Mol Pharmacol, 1, 93, 10.2174/1874467210801020093 Leonard, 2003, The role of ABC transporters in clinical practice, Oncologist, 8, 411, 10.1634/theoncologist.8-5-411 Gouaze, 2005, Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs, Cancer Res, 65, 3861, 10.1158/0008-5472.CAN-04-2329 Gottesman, 2002, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat Rev Cancer, 2, 48, 10.1038/nrc706 Eckford, 2009, ABC efflux pump-based resistance to chemotherapy drugs, Chem Rev, 109, 2989, 10.1021/cr9000226 Schrag, 2004, American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays, J Clin Oncol, 22, 3631, 10.1200/JCO.2004.05.065 Mohan, 2009, Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis, J Nucl Med, 50, 376, 10.2967/jnumed.108.055988 Claret, 2009, Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics, J Clin Oncol, 27, 4103, 10.1200/JCO.2008.21.0807 Kern, 1990, Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures, J Natl Cancer Inst, 82, 582, 10.1093/jnci/82.7.582 Samson, 2004, Chemotherapy sensitivity and resistance assays: a systematic review, J Clin Oncol, 22, 3618, 10.1200/JCO.2004.04.077 Kim, 2009, In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study, J Cancer Res Clin Oncol, 10.1007/s00432-009-0598-0 Karam, 2009, Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer, Gynecol Oncol, 10.1016/j.ygyno.2009.02.022 DeVita, 2009 Arceci, 1993, Clinical significance of P-glycoprotein in multidrug resistance malignancies, Blood, 81, 2215, 10.1182/blood.V81.9.2215.2215 Olesen, 2003, Validation and clinical implication of a quantitative real-time PCR determination of MDR1 gene expression: comparison with semi-quantitative PCR in 101 patients with acute myeloid leukemia, Eur J Haematol, 70, 296, 10.1034/j.1600-0609.2003.00060.x Punyammalee, 1997, Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer, J Med Assoc Thai, 80, S162 Orina, 2009, Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database, Mol Cancer Ther, 8, 2057, 10.1158/1535-7163.MCT-09-0256 Fujimaki, 2002, Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia, Clin Chem, 48, 811, 10.1093/clinchem/48.6.811 Zhang, 2007, Use of arrays to investigate the contribution of ATP-binding cassette transporters to drug resistance in cancer chemotherapy and prediction of chemosensitivity, Cell Res, 17, 311, 10.1038/cr.2007.15 van der Holt, 2006, ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients, Clin Pharmacol Ther, 80, 427, 10.1016/j.clpt.2006.07.005 Zhang, 1991, Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation, J Biol Chem, 266, 18224, 10.1016/S0021-9258(18)55258-3 Kramer, 1995, Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype, Br J Cancer, 71, 670, 10.1038/bjc.1995.133 Yang, 1996, Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells, Cancer Res, 56, 3490 Kannan, 2009, Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications, Clin Pharmacol Ther, 86, 368, 10.1038/clpt.2009.138 Homolya, 1996, A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells, Br J Cancer, 73, 849, 10.1038/bjc.1996.151 Piwnica-Worms, 1993, Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex, Cancer Res, 53, 977 Fairchild, 1987, Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells, Cancer Res, 47, 5141 Rogan, 1984, Reversal of adriamycin resistance by verapamil in human ovarian cancer, Science, 224, 994, 10.1126/science.6372095 Akiyama, 1985, Isolation and genetic characterization of human KB cell lines resistant to multiple drugs, Somat Cell Mol Genet, 11, 117, 10.1007/BF01534700 Lai, 1991, P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines, Int J Cancer, 49, 696, 10.1002/ijc.2910490512 Patwardhan, 2009, A new mixed-backbone oligonucleotide against glucosylceramide synthase Sensitizes multidrug-resistant tumors to apoptosis, PLoS One, 4, e6938, 10.1371/journal.pone.0006938 Diaz, 2000, Molecular recognition of taxol by microtubules. Kinetics and thermodynamics of binding of fluorescent taxol derivatives to an exposed site, J Biol Chem, 275, 26265, 10.1074/jbc.M003120200 Rinaldi, 2006, First line chemotherapy in advanced or metastatic NSCLC, Ann Oncol, 17, v64, 10.1093/annonc/mdj953 Marcus, 2006, Farnesyltransferase inhibitors reverse taxane resistance, Cancer Res, 66, 8838, 10.1158/0008-5472.CAN-06-0699 Diaz, 2003, Fast kinetics of Taxol binding to microtubules. Effects of solution variables and microtubule-associated proteins, J Biol Chem, 278, 8407, 10.1074/jbc.M211163200 Walle, 1998, Taxol transport by human intestinal epithelial Caco-2 cells, Drug Metab Dispos, 26, 343 Sela, 1995, Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil, J Natl Cancer Inst, 87, 123, 10.1093/jnci/87.2.123 Al-Hajj, 2003, Prospective identification of tumorigenic breast cancer cells, Proc Natl Acad Sci USA, 100, 3983, 10.1073/pnas.0530291100 Gupta, 2010, Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthase (GlcT-1), J Lipid Res, 51, 866, 10.1194/jlr.D002949 Liu, 2008, A role for ceramide in driving cancer cell resistance to doxorubicin, FASEB J, 22, 2541, 10.1096/fj.07-092981 Kessel, 1991, Characterization of multidrug resistance by fluorescent dyes, Cancer Res, 51, 4665 Jang, 2001, Determinants of paclitaxel uptake, accumulation and retention in solid tumors, Invest New Drugs, 19, 113, 10.1023/A:1010662413174 Jang, 2001, Kinetics of P-glycoprotein-mediated efflux of paclitaxel, J Pharmacol Exp Ther, 298, 1236 Gottesman, 1993, Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu Rev Biochem, 62, 385, 10.1146/annurev.bi.62.070193.002125 Rosati, 2004, Bodipy-FL-verapamil: a fluorescent probe for the study of multidrug resistance proteins, Cell Oncol, 26, 3